Home › Urothelial (Transitional Cell) Carcinoma › Texas › Tyler
Urothelial (Transitional Cell) Carcinoma clinical trials in Tyler, TX
4 studies for Urothelial (Transitional Cell) Carcinoma are looking for participants at sites in and around Tyler (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RecruitingPhase 1
- Exelixis Clinical Site #70, Tyler
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
RecruitingPhase 3
- Texas Oncology - Northeast Texas, Tyler
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
- USO - Texas Oncology - Northeast Texas, Tyler
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
- The University of Texas Health Science Center at Tyler, Tyler
Urothelial (Transitional Cell) Carcinoma trials in other cities
- Nashville, TN23 studies
- New York City, NY22 studies
- Dallas, TX18 studies
- Edison, NJ18 studies
- Houston, TX18 studies
- Los Angeles, CA17 studies
- Queens, NY15 studies
- Chicago, IL14 studies
- Arlington, VA12 studies
- San Antonio, TX11 studies
- Boston, MA11 studies
- Austin, TX10 studies
Other studies in Tyler
- Non-Small Cell Lung Cancer20 studies
- Crohn's Disease16 studies
- Ulcerative Colitis14 studies
- Colorectal Cancer8 studies
- Heart Failure8 studies
- Cancer (all types)7 studies
- Ovarian Cancer7 studies
- Endometrial Cancer6 studies
- Head and Neck Squamous Cell Carcinoma6 studies
- Breast Cancer6 studies
- Metastatic Cancer5 studies
- Inflammatory Bowel Disease5 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.